Q1 25 EPS
$-0.45
MISS 7.14%
Est. $-0.42
Q1 25 Revenue
$3.1M
MISS 3.26%
Est. $3.2M
vs S&P Since Q1 25
+355.7%
BEATING MARKET
LQDA +385.5% vs S&P +29.8%
Market Reaction
Did LQDA Beat Earnings? Q1 2025 Results
Liquidia delivered a disappointing first quarter, missing on both top and bottom lines as the company presses toward what may be the most consequential regulatory moment in its history. The loss per share of $0.45 came in wider than the $0.42 consens… Read more Liquidia delivered a disappointing first quarter, missing on both top and bottom lines as the company presses toward what may be the most consequential regulatory moment in its history. The loss per share of $0.45 came in wider than the $0.42 consensus estimate, a 7.14% miss, while revenue of $3.12 million fell 3.26% short of the $3.23 million analysts had expected, though it did grow 5.0% year-over-year, driven by the Sandoz promotion agreement for Treprostinil Injection. The primary culprit behind the widening net loss, which reached $38.37 million versus $30.08 million a year ago, was a 48% surge in general and administrative expenses to $30.06 million, as Liquidia redeployed personnel and resources toward commercial launch preparation for YUTREPIA ahead of the FDA's May 24, 2025 PDUFA goal date. With $169.76 million in cash and up to $100.00 million in additional financing secured from HealthCare Royalty, the company says it is positioned to move quickly toward commercialization, though at least one analyst has raised concerns about YUTREPIA's ability to differentiate itself in what promises to be a competitive launch environment.
Key Takeaways
- • Revenue primarily from Sandoz promotion agreement for Treprostinil Injection sales in the U.S.
- • Year-over-year revenue increase driven by favorable gross-to-net returns adjustments partially offset by lower sales volumes
- • G&A expenses increased 48% YoY due to personnel shift from R&D to YUTREPIA commercial launch preparation
- • R&D expenses declined 31% YoY due to personnel reallocation to commercialization activities
- • Interest expense increased due to higher borrowings under HealthCare Royalty agreement
LQDA YoY Financials
Q1 2025 vs Q1 2024, source: SEC Filings
LQDA Revenue by Segment
With YoY comparisons, source: SEC Filings
“With the FDA's PDUFA goal date on the YUTREPIA NDA just over two weeks away, we remain focused on ensuring that we are prepared to make YUTREPIA commercially available in the quickest time possible if granted full approval. We continue to believe that YUTREPIA has the potential to be the prostacyclin of first choice for patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).”
— Roger Jeffs, Q1 2025 Earnings Press Release
LQDA Earnings Trends
LQDA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
LQDA EPS Trend
Earnings per share: estimate vs actual
LQDA Revenue Trend
Quarterly revenue: estimate vs actual
LQDA Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $0.41 | $0.52 | +28.08% | $132.9M | +11.27% |
| Q4 25 MISS FY | $0.33 | $0.15 | -55.09% | $92.0M | +5.18% |
| FY Full Year | — | $-0.80 | — | $158.3M | — |
| Q3 25 BEAT | $-0.33 | $-0.04 | +88.00% | $54.3M | +188.17% |
| Q2 25 MISS | $-0.39 | $-0.49 | -24.84% | $8.8M | +126.96% |
| Q1 25 MISS | $-0.42 | $-0.45 | -7.14% | $3.1M | -3.26% |